Medicinal and edible traditional Chinese medicine composition for treating hyperuricemia kidney injury and application of medicinal and edible traditional Chinese medicine composition

Abstract

The invention discloses a medicinal and edible traditional Chinese medicine composition for treating hyperuricemia renal injury. The traditional Chinese medicine composition is prepared from the following raw materials in parts by mass: 30-120 parts of clerodendranthus spicatus and 10-30 parts of cordyceps sobolifera. The invention also discloses application of the medicinal and edible traditional Chinese medicine composition in preparation of medicines for preventing and treating hyperuricemia kidney injury or hyperuricemia. The traditional Chinese medicine composition provided by the invention is homologous in medicine and food, high in safety, simple and fine in medicine flavor, definite in curative effect, wide in applicable crowd and low in price. Experimental results show that the traditional Chinese medicine composition provided by the invention can significantly reduce blood uric acid and serum creatinine levels, and alleviate pathological injury of the kidney. Therefore, the traditional Chinese medicine composition preparation provided by the invention is expected to be developed into a new generation of medicinal and edible health products for preventing and treating the hyperuricemia kidney injury.

Description

Technical Field

[0001] The invention belongs to the technical field of research on traditional Chinese medicine compound prescriptions, and specifically relates to a traditional Chinese medicine composition having both medicinal and edible properties for treating hyperuricemia renal injury and an application thereof. Background Art

[0002] Hyperuricemia is the second most common metabolic disease in my country after diabetes, and is an independent risk factor for a variety of chronic diseases, including hypertension, coronary heart disease, and diabetes. The kidney is the main excretion organ of uric acid, and the onset of kidney damage caused by hyperuricemia is insidious. It can not only directly cause kidney lesions and induce acute kidney injury or chronic kidney disease, but also accelerate the development of existing chronic kidney disease to end-stage renal disease. There are no obvious symptoms in the early stages of hyperuricemia kidney damage, and it is often not discovered until acute uric acid nephropathy, urate kidney stones, or late-stage chronic uric acid nephropathy occur. It is very easy to be missed, misdiagnosed, and delayed in treatment.

[0003] The main treatment strategy for hyperuricemia renal injury is lifestyle intervention combined with uric acid-lowering drug therapy, mainly using drugs such as inhibiting uric acid synthesis (such as allopurinol, febuxostat, and torbisostat), promoting uric acid excretion (such as benzbromarone, probenecid, and lesinad), and catalyzing uric acid oxidative metabolism (such as rasburicase and pegolocase). However, the above-mentioned drugs still have various disadvantages. For example, allopurinol may cause fatal delayed hypersensitivity reactions, febuxostat may increase the risk of cardiovascular events, benzbromarone has the risk of causing kidney stones and has certain liver toxicity, and new uric acid-lowering drugs such as rasburicase and pegolocase are expensive.

[0004] More and more reports show that Chinese medicine is effective in lowering uric acid and has few adverse reactions. Existing Chinese medicine compound preparations for lowering uric acid have the following problems: too large a prescription, poor taste, inconvenient to take, and limited applicable population. Therefore, it is necessary to develop new Chinese medicine compound preparations for hyperuricemia renal injury, and meet the following conditions: medicine and food are of the same origin, high safety, simple and refined taste, definite efficacy, and a wide range of applicable populations. Summary of the invention

[0005] The purpose of the present invention is to provide a Chinese medicine composition for treating hyperuricemia renal injury.

[0006] The present invention also aims to provide the use of the above-mentioned Chinese medicine composition in the preparation of drugs for preventing and treating hyperuricemia renal injury or hyperuricemia.

[0007] The above-mentioned first purpose of the present invention can be achieved through the following technical scheme: a Chinese medicine composition with medicinal and edible properties for treating hyperuricemia renal injury, the Chinese medicine composition is composed of the following raw materials in parts by mass: 30-120 parts of kidney tea and 10-30 parts of cicada flowers.

[0008] Preferably, the Chinese medicine composition is composed of the following raw materials in parts by mass: 30-60 parts of kidney tea and 10-30 parts of cicada flower.

[0009] As a preferred embodiment of the present invention, the Chinese medicine composition is composed of the following raw materials in parts by weight: 30 parts of kidney tea and 10 parts of cicada flower.

[0010] As a preferred embodiment of the present invention, the Chinese medicine composition is composed of the following raw materials in parts by weight: 30 grams of kidney tea and 30 grams of cicada flower.

[0011] As a preferred embodiment of the present invention, the Chinese medicine composition is composed of the following raw materials in parts by weight: 120 parts of kidney tea and 10 parts of cicada flower.

[0012] As a preferred embodiment of the present invention, the Chinese medicine composition is composed of the following raw materials in parts by weight: 120 grams of kidney tea and 30 grams of cicada flower.

[0013] The Chinese medicinal composition for treating hyperuricemia renal injury with both medicine and food of the present invention has the advantages of being both medicine and food, simple and refined medicinal flavor, definite efficacy, wide applicability, and low adverse reactions.

[0014] The raw materials of the Chinese medicine composition for treating hyperuricemia renal injury of the present invention include:

[0015] Tea of ​​the kidney is a perennial herbaceous plant of the Lamiaceae family. Because its filaments extend out of the lip-shaped corolla and look like cat whiskers, it is also called cat whisker grass. Tea of ​​the kidney tastes slightly bitter and is cool in nature. It can clear away heat and dampness, relieve stranguria and expel stones. It is a very common and widely used folk herbal medicine in Southeast Asia and is inexpensive. At present, more than 200 compounds have been isolated and identified from tea of ​​the kidney, including phenolic compounds, flavonoid compounds, coumarin compounds, diterpenoid compounds, tea of ​​the kidney alkyl glycoside A, tea of ​​the kidney alkyl glycoside B, volatile oils, lignans, organic acids, polysaccharides and amino acids. Modern research shows that tea of ​​the kidney has multiple pharmacological effects such as anti-oxidation, free radical scavenging, anti-inflammatory, diuretic, uric acid lowering, and stone-promoting. In addition, tea of ​​the kidney also plays a positive role in delaying renal interstitial fibrosis and glomerular sclerosis.

[0016] Cicada fungus, commonly known as big cordyceps, is the oldest cordyceps that is infected and parasitized by the Cordyceps fungus before the cicada emerges. It eventually transforms into an insect-borne fungus. Cicada fungus is sweet in taste and cold in nature. It has the effects of invigorating qi and strengthening the spleen, nourishing the kidney and nourishing yin. Although its status in traditional Chinese medicine is not as high as that of Cordyceps sinensis, its medicinal ingredients are similar to those of Cordyceps sinensis and can be regarded as an affordable substitute for Cordyceps sinensis. At present, there are few studies on the chemical components related to cicada fungus. The known components mainly include ergosterols, nucleotides, fatty acids and polysaccharides, which have anti-fibrosis, anti-oxidative stress, anti-inflammatory, immune regulation, and improvement of renal function. Cicada fungus can play a protective role in the kidneys through multiple targets, and has broad application prospects and great development potential.

[0017] The combination of the above two medicines forms a combination prescription, which takes both deficiency and excess into consideration, clears away heat and dampness, removes stones and promotes diuresis, while replenishing vital energy and protecting kidney function.

[0018] The above-mentioned second purpose of the present invention can be achieved by the following technical scheme: the use of the above-mentioned Chinese medicine composition with medicinal and edible properties for treating hyperuricemia renal injury in the preparation of drugs for preventing and treating hyperuricemia renal injury or hyperuricemia.

[0019] The medicine comprises the above-mentioned traditional Chinese medicine composition and / or its extract and a pharmaceutically acceptable carrier.

[0020] Preferably, the dosage form of the drug is decoction, tea substitute, tablet, pill, granule, powder, capsule, extract or oral solution.

[0021] For example, the present invention can prepare the extracts of various raw materials and pharmaceutically acceptable carriers into dosage forms such as tea substitutes, tablets, pills, granules, powders, capsules, extracts or oral liquids. Decoctions, tea substitutes or capsules are preferred.

[0022] Taking decoction as an example, when the raw materials of the Chinese medicine composition provided by the present invention are made into decoction, each raw material is put into a decoction container, 5 to 10 times the amount of water is added and boiled for 1 to 3 times, the decoctions are combined, filtered, and concentrated to make a decoction.

[0023] Taking tea substitute as an example, when the raw materials of the traditional Chinese medicine composition provided by the present invention are made into tea substitute, the cicada fungus is dried at low temperature and ultrafinely ground to form cicada fungus powder, kidney tea and boiling water are added to a heat-insulating container, and soaked for 10 to 30 minutes. When the water temperature drops below 60°C, the cicada fungus powder is added and taken orally.

[0024] Taking tablets as an example, when the extracts of the raw materials of the traditional Chinese medicine composition provided by the present invention are made into tablets, the extracts of the raw materials and corn starch, and lubricant magnesium stearate are added when necessary, mixed evenly, granulated, and then compressed into tablets.

[0025] Taking granules as an example, when the extracts of the raw materials of the traditional Chinese medicine composition provided by the present invention are made into granules, the extracts of the raw materials and the diluent corn starch are evenly mixed, granulated, and dried to make granules.

[0026] Taking capsules as an example, when the extracts of the raw materials of the traditional Chinese medicine composition provided by the present invention are made into capsules, the extracts of the raw materials and the carrier corn starch are evenly mixed, granulated, and then filled into capsules to make capsules.

[0027] Taking the extract as an example, when the raw materials of the traditional Chinese medicine composition provided by the present invention are made into an extract, each raw material is soaked in cold water for 15 minutes, and then 10 to 15 times the mass of water is added and decocted twice, each time for 2 hours, and the medicinal juice obtained by the two decoctions is concentrated after the residue is removed to a water content of 15 to 20% to prepare an extract.

[0028] Taking oral liquid as an example, when the extracts of the raw materials of the traditional Chinese medicine composition provided by the present invention are made into oral liquid, the extracts of the raw materials are dissolved in distilled water, filtered, and the pH value is adjusted to make the oral liquid.

[0029] As a preferred embodiment of the present invention, the method for preparing the drug provided by the present invention comprises the following steps:

[0030] (1) taking 30 to 120 parts of kidney tea and 10 to 30 parts of cicada flower by weight, putting them into a decoction container, adding 5 to 10 times the amount of water and boiling for 1 to 3 times, combining the decoctions, filtering, and concentrating to obtain a concentrated solution, i.e., an extract;

[0031] (2) The extract obtained in step (1) is mixed with a pharmaceutically acceptable carrier to prepare a drug in the form of tablets, pills, granules, powders, capsules, extracts or oral solutions.

[0032] The present invention has the following advantages:

[0033] (1) The present invention is based on clinical practice, taking both deficiency and excess into consideration, and adopts kidney tea which can clear away heat and dampness, relieve stranguria and expel stones, and cicada flower which can invigorate qi and invigorate spleen, nourish kidney and nourish yin. The proportion is scientific and reasonable, the formula is simple and refined, the curative effect is definite, the price is low, and it is applicable to a wide range of people.

[0034] (2) The Chinese medicine combination provided by the present invention has a comprehensive effect of multiple links and multiple targets, which can effectively reduce the level of blood uric acid, alleviate kidney pathological damage, and protect kidney function; experimental results show that the Chinese medicine combination provided by the present invention can significantly reduce the levels of blood uric acid and blood creatinine, alleviate the degree of renal tubular atrophy and brush border shedding, and reduce interstitial inflammatory cell infiltration.

[0035] (3) The extract of the Chinese medicine combination provided by the present invention can be conveniently prepared into a variety of dosage forms with pharmaceutical carriers, which is convenient for clinical use. In addition, experimental results show that the Chinese medicine combination provided by the present invention has no adverse effects on liver function, is safe to use, and has reliable efficacy. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 This is a graph showing the effect of the medicine prepared by using the Chinese medicine composition provided in Example 1 and Example 2 on serum uric acid, blood creatinine, alanine aminotransferase and aspartate aminotransferase in hyperuricemia rats in Example 8 of the present invention;

[0037] Figure 2 HE staining and Masson staining of renal tissue pathology of rats with hyperuricemia using the medicine prepared by the Chinese medicine composition provided in Example 1 and Example 2 in Example 8 of the present invention;

[0038] Figure 3 This is an electron microscopic image of the effect of the drug prepared using the Chinese medicine composition provided in Examples 1 and 2 in Example 8 of the present invention on rat renal tubular epithelial cells. DETAILED DESCRIPTION

[0039] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0040] Example 1

[0041] The present embodiment provides a Chinese medicine composition for treating hyperuricemia and kidney damage, which is composed of the following raw materials: 30 g of kidney tea and 10 g of cicada flower.

[0042] When the raw materials of the Chinese medicine composition provided by the present invention are made into a decoction, the raw materials are put into a decoction container, 8 times the amount of water is added and decocted twice, the decoctions are combined, filtered, and concentrated to make a decoction.

[0043] Example 2

[0044] The present embodiment provides a Chinese medicine composition for treating hyperuricemia renal injury, which is a food-medicine composition. The Chinese medicine composition is composed of the following raw materials in terms of mass: 60 g of kidney tea and 20 g of cicada flower.

[0045] When the raw materials of the Chinese medicine composition provided in this embodiment are made into a decoction, each raw material is placed in a decoction container, 8 times the amount of water is added and decocted twice, the decoctions are combined, filtered, and concentrated to the same volume as in Example 1 to prepare a decoction.

[0046] Example 3

[0047] The present embodiment provides a Chinese medicine composition for treating hyperuricemia and kidney damage, which is composed of the following raw materials: 30 g of kidney tea and 10 g of cicada flower.

[0048] When the raw materials of the Chinese medicine composition of this embodiment are made into a tea substitute, the cicada fungus is dried at low temperature and ultrafinely ground to form cicada fungus powder, kidney tea and boiling water are added to a heat-insulating container and soaked for 20 minutes. When the water temperature drops below 60°C, the cicada fungus powder is added and taken orally.

[0049] Example 4

[0050] The present embodiment provides a Chinese medicine composition for treating hyperuricemia renal injury, which is composed of the following raw materials: 30 g of kidney tea and 30 g of cicada flower.

[0051] When the extracts of the raw materials of the traditional Chinese medicine composition provided in this embodiment are made into tablets, the extracts of the raw materials and corn starch, and the lubricant magnesium stearate are added when necessary, mixed evenly, granulated, and then compressed into tablets; the preparation method of the extracts of the raw materials is as follows: take kidney tea and cicada flower according to the above mass, put them into a decoction container, add 8 times the amount of water and decoct twice, combine the decoctions, filter, and concentrate to obtain a concentrated solution, i.e., the extract.

[0052] Example 5

[0053] The present embodiment provides a Chinese medicine composition for treating hyperuricemia renal injury, which is composed of the following raw materials: 120 g of kidney tea and 10 g of cicada flower.

[0054] When the extracts of the raw materials of the Chinese medicine composition provided in this embodiment are made into granules, the extracts of the raw materials and the diluent corn starch are evenly mixed, granulated, and dried to make granules; the preparation method of the extracts of the raw materials is as follows: take kidney tea and cicada flower according to the above mass, put them into a decoction container, add 8 times the amount of water and decoct twice, combine the decoctions, filter, and concentrate to obtain a concentrated solution, i.e., the extract.

[0055] Example 6

[0056] The present embodiment provides a Chinese medicine composition for treating hyperuricemia renal injury, which is a food-medicine composition. The Chinese medicine composition is composed of the following raw materials in terms of mass: 120 g of kidney tea and 30 g of cicada flower.

[0057] When the extracts of the raw materials of the traditional Chinese medicine composition provided in this embodiment are made into capsules, the extracts of the raw materials and the carrier corn starch are evenly mixed, granulated, and then put into capsules to make capsules; the preparation method of the extracts of the raw materials is as follows: take kidney tea and cicada flower according to the above mass, put them into a decoction container, add 8 times the amount of water and decoct twice, combine the decoctions, filter, and concentrate to obtain a concentrated solution, i.e., the extract.

[0058] Example 7

[0059] The present embodiment provides a Chinese medicine composition for treating hyperuricemia renal injury, which is a food-medicine composition. The Chinese medicine composition is composed of the following raw materials in terms of mass: 60 g of kidney tea and 20 g of cicada flower.

[0060] When the extract of the Chinese medicine composition provided in this embodiment is made into an extract, each raw material is soaked in cold water for 15 minutes, and then 10 times the weight of water is added and decocted twice, each time for 2 hours. The decoction obtained by the two decoctions is concentrated after the residue is removed to a water content of 15-20% to prepare an extract.

[0061] Example 8

[0062] Animal experiments

[0063] 1. Experimental Animals

[0064] Six-week-old male SPF rats, weighing 200 ± 20 g, were purchased from Guangdong Weitonglihua Experimental Animal Technology Co., Ltd., with use license number: SYXK (Guangdong) 2023-0094; production license number: SCXK (Guangdong) 2022-0063.

[0065] 2. Model construction and grouping

[0066] All rats were adaptively fed for 1 week. According to the previous research experience of the research group, a rat model of high uric acid renal injury was constructed by oral gavage with potassium oxonate (750 mg / kg) combined with uric acid (300 mg / kg). The rats were randomly divided into a normal group, a model group, a low-dose group of kidney tea-cicada in Example 1, a high-dose group of kidney tea-cicada in Example 2, and a febuxostat group, with 8 rats in each group. The oral gavage dose was calculated based on the body surface area, and the per kilogram of body weight was about 6.3 times the clinical dose for humans. The oral gavage dose of rats in the low-dose group of kidney tea-cicada was 4.2 g / kg body weight per day, the oral gavage dose of rats in the high-dose group of kidney tea-cicada was 8.4 g / kg body weight per day, and the oral gavage dose of rats in the febuxostat group was 4.2 mg / kg body weight per day. Continuous oral gavage intervention for 3 weeks.

[0067] 3. Specimen collection

[0068] The rats were fasted for more than 12 hours overnight. After anesthesia, blood was collected from the abdominal aorta, serum was separated, and stored at -80°C for later use. The capsule of the kidney tissue was peeled off, the kidney weight was measured, and some parts were cut into 1 mm 3 Small pieces were quickly placed in 2.5% glutaraldehyde fixative and fixed at 4°C overnight for later use; some were stored in 4% paraformaldehyde and fixed at 4°C for more than 24 hours, dehydrated in an automatic dehydrator, embedded in paraffin, and cut into 3μm thick slices for later use.

[0069] 4. Index detection

[0070] MS-480 automatic biochemical analyzer was used to analyze and detect biochemical indicators such as serum uric acid, serum creatinine, urea, alanine aminotransferase and aspartate aminotransferase in serum, and urine creatinine and urine uric acid levels in urine were detected. The uric acid excretion fraction was calculated, and the changes in the experimental endpoint-related indicators of rats in the normal group, model group, kidney tea-cicada low-dose group, kidney tea-cicada high-dose group, and febuxostat group were compared. Graphpad Prism 9.0.0 software was used for data processing and drawing. The quantitative data were expressed as mean ± standard deviation (x ± s). One-way analysis of variance was used for comparison between groups of normally distributed data, and non-parametric test was used for comparison between groups of non-normally distributed data. HE and Masson staining were used to observe the pathological changes of renal tissues, and electron microscopy was used to observe the ultrastructure of renal tubular cells.

[0071] 5. Experimental results

[0072] like Figure 1 As shown:

[0073] After oral administration of potassium oxonate and uric acid for 3 weeks, compared with the control group, the levels of serum uric acid and serum creatinine in the model group were significantly increased (P<0.001), and the fractional excretion of uric acid was significantly decreased (P<0.05), and the differences were statistically significant. Blood urea showed an increasing trend (P=0.139), but the difference was not statistically significant.

[0074] Compared with the model group, the blood uric acid and blood creatinine levels of rats in the low-dose kidney tea-cicada group, high-dose kidney tea-cicada group, and febuxostat group were significantly decreased (P<0.001), and the differences were statistically significant.

[0075] In addition, there was no statistical difference in the levels of alanine aminotransferase and aspartate aminotransferase among the rats in each group, indicating that low-dose and high-dose kidney tea-cicada fungus intervention did not cause liver function damage.

[0076] Figure 1 The results showed that this modeling method can induce a significant increase in blood uric acid and blood creatinine in rats, and kidney tea-cicada fungus intervention can significantly reduce the levels of blood uric acid and blood creatinine.

[0077] The renal tissue sections of rats in each group were stained with HE and Masson. Figure 2Shown, magnification is 100 times, scale bar = 50 μm.

[0078] from Figure 2 It can be seen that:

[0079] HE staining showed that the glomeruli and tubules of the control group rats were intact and the tubules were dense.

[0080] In the model group, the renal tubular epithelial cells of rats were extensively vacuolar and necrotic, the tubular epithelium was atrophied, the brush border fell off, the number of cell nuclei was significantly reduced, and focal inflammatory cell infiltration was observed in the renal interstitium.

[0081] Compared with the model group, after low-dose kidney tea-cicada intervention, tubular atrophy and brush border shedding were alleviated, and interstitial inflammatory cell infiltration was reduced.

[0082] The renal pathological damage of rats in the high-dose kidney tea-cicada group and febuxostat group was further alleviated than that in the low-dose kidney tea-cicada group.

[0083] Masson staining showed that there was no obvious collagen deposition in the renal interstitium of rats in the control group, while the blue-stained area of ​​the renal interstitium of rats in the model group increased significantly, indicating that there was extensive collagen deposition and obvious fibrosis changes.

[0084] Compared with the model group, the blue-stained area of ​​renal interstitium of rats in the low-dose kidney tea-cicada group, high-dose kidney tea-cicada group and febuxostat group was significantly reduced, indicating that the degree of fibrosis in the three groups of rats was alleviated.

[0085] Figure 2 The results showed that this modeling method can induce pathological damage to the kidneys of rats, accompanied by extensive collagen deposition and fibrosis, and kidney tea-cicadae intervention can effectively alleviate pathological damage to the kidneys.

[0086] The renal tissue and ultrastructure of rats in each group were observed using transmission electron microscopy. Figure 3 As shown, the upper layer shows a magnification of 6000 times, scale bar = 2μm; the lower layer shows a magnification of 25000 times, scale bar = 500nm. White arrows indicate healthy mitochondria, black arrows indicate damaged mitochondria, and red arrows indicate mitophagosomes.

[0087] The structure of renal tubular epithelial cells in the control group rats was normal, the mitochondria were slender in shape, intact in structure, the mitochondrial cristae were continuous, and the autophagosomes wrapped around the aged mitochondria to form mitophagosomes.

[0088] The tubular epithelial cells of rats in the model group showed vacuolar degeneration and necrosis, the mitochondria were spherical or rod-shaped, the mitochondrial cristae were broken, the matrix was vesicularized, and some were even vacuolated. The mitochondria were swollen and ruptured, mitochondrial fragmentation occurred, damaged mitochondria were excessively accumulated, and no mitochondrial autophagosome formation was found under the visual field.

[0089] Compared with the model group, the degree of renal tubular vacuolar degeneration of rats in the low-dose, high-dose Kidney Tea-Cicada Flower and Febuxostat groups was alleviated, the number of damaged mitochondria was reduced, and autophagosomes wrapped around damaged mitochondria to form mitochondrial autophagosomes.

[0090] Figure 3 The results showed that this modeling method can induce vacuolar degeneration and necrosis of rat renal tubular epithelial cells, accompanied by extensive mitochondrial damage. Kidney tea-cicadae intervention can induce mitochondrial autophagosome formation, accelerate the clearance of damaged mitochondria, and alleviate tubular epithelial cell damage.

[0091] Therefore, the edible and medicinal Chinese medicine composition of the present invention can be added with and / or its extract and a pharmaceutically acceptable carrier to prepare a tea substitute, tablets, pills, granules, powders, capsules, extracts or oral liquids, etc., for the preparation of drugs for preventing and treating hyperuricemia renal injury or hyperuricemia.

[0092] The specific embodiments described above further illustrate the purpose, technical solutions and beneficial effects of the present invention. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the scope of protection of the present invention. It is particularly pointed out that for those skilled in the art, any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention should be included in the scope of protection of the present invention.

Claims

1. A Chinese medicine composition for treating hyperuricemia renal injury, characterized in that: The Chinese medicine composition is composed of the following raw materials in parts by weight: 30-120 parts of kidney tea and 10-30 parts of cicada flowers.

2. The Chinese medicinal composition for treating hyperuricemia renal injury according to claim 1, characterized in that: The Chinese medicine composition is composed of the following raw materials in parts by weight: 30-60 parts of kidney tea and 10-30 parts of cicada flowers.

3. The Chinese medicine composition for treating hyperuricemia renal injury according to claim 2, characterized in that: The Chinese medicine composition is composed of the following raw materials in parts by weight: 30 parts of kidney tea and 10 parts of cicada flower.

4. The Chinese medicinal composition for treating hyperuricemia renal injury according to claim 1, characterized in that: The Chinese medicine composition is composed of the following raw materials in parts by weight: 30 grams of kidney tea and 30 grams of cicada flower.

5. The Chinese medicinal composition for treating hyperuricemia renal injury according to claim 1, characterized in that: The Chinese medicine composition is composed of the following raw materials in parts by weight: 120 parts of kidney tea and 10 parts of cicada flower.

6. The Chinese medicinal composition for treating hyperuricemia renal injury according to claim 1, characterized in that: The Chinese medicine composition is composed of the following raw materials in parts by weight: 120 grams of kidney tea and 30 grams of cicada flower.

7. Use of the Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a drug for preventing and treating hyperuricemia renal injury or hyperuricemia.

8. The use according to claim 7, characterized in that: The medicine comprises the Chinese medicine composition and / or its extract according to any one of claims 1 to 6 and a pharmaceutically acceptable carrier.

9. The use according to claim 8, characterized in that: The dosage form of the medicine is decoction, tea substitute, tablet, pill, granule, powder, capsule, extract or oral solution.

Images